title: The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial.
authors.affiliation: School of Pharmacy, Northeastern University, 360 Huntington Ave, TF R218, Boston, MA, 02115, USA.
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Duprey
authors.affiliation: Department of Critical Care, Hafer Albatin Central Hospital, Riyadh, Saudi Arabia.
authors.forename: Nada
authors.initials: N
authors.lastname: Al-Qadheeb
authors.affiliation: Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Russel
authors.initials: R
authors.lastname: Roberts
authors.affiliation: Division of Critical Care, McGill University Health Centre, Montreal, QC, Canada.
authors.forename: Yoanna
authors.initials: Y
authors.lastname: Skrobik
authors.affiliation: Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA, USA.
authors.forename: Greg
authors.initials: G
authors.lastname: Schumaker
authors.affiliation: School of Pharmacy, Northeastern University, 360 Huntington Ave, TF R218, Boston, MA, 02115, USA. j.devlin@neu.edu.|Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA, USA. j.devlin@neu.edu.
authors.forename: John W
authors.initials: JW
authors.lastname: Devlin
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003693:Delirium / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007362:Intensive Care Units; D008133:Long QT Syndrome / Q000503:physiopathology*; D008875:Middle Aged; D012121:Respiration, Artificial
chemical_list: D014150:Antipsychotic Agents; D006220:Haloperidol